High-intensity focused ultrasound (HIFU) for treatment of hepatocellular carcinoma
Record ID 32013000228
English
Authors' recommendations:
Hepatocellular carcinoma (HCC) is a primary malignancy of the liver that accounts for more than 80% of all liver cancer types. HCC is an aggressive tumor that is one of the most common causes of cancer death worldwide, with an annual incidence of more than 550,000 new cases per year. The overall 5-year survival rate for HCC is 14%, and this rate decreases to 4% among patients who are diagnosed at later stages. Early-stage cancer can sometimes be treated surgically in patients with sufficient healthy liver tissue, but in more advanced stages of disease, fewer surgical options exist. Only about 5% of patients are eligible for tumor resection, which is indicated in cases with solitary tumors that are confined to the liver and normal or well-preserved liver function. Patients with localized or locally advanced, unresectable cancer may be treated with liver transplantation, percutaneous radiofrequency ablation, transarterial chemoembolization (TACE), or other forms of ablation.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
The report may be purchased from:http://www.hayesinc.com/hayes/crd/?crd=14629
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Humans
- Carcinoma, Hepatocellular
- High-Intensity Focused Ultrasound Ablation
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2012 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.